Cargando…

USP8 Somatic Mutations in Cushing’s Disease and Silent Corticotropinomas

Background: Somatic mutations in the ubiquitin-specific peptidase 8 (USP8) gene have been described in Cushing’s disease (CD). These mutations increase proopiomelanocortin transcription resulting in ACTH production and seem to correlate with somatostatin receptor type 5 (SST5) expression. Aims: Scre...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamback, Elisa Baranski, Lima, Carlos Henrique de Azeredo, Miranda, Renan Lyra, Guterres, Alexandro, Andreiuolo, Felipe, Wildemberg, Luiz Eduardo Armondi, Gadelha, Monica Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090680/
http://dx.doi.org/10.1210/jendso/bvab048.1328
_version_ 1783687341689274368
author Lamback, Elisa Baranski
Lima, Carlos Henrique de Azeredo
Miranda, Renan Lyra
Guterres, Alexandro
Andreiuolo, Felipe
Wildemberg, Luiz Eduardo Armondi
Gadelha, Monica Roberto
author_facet Lamback, Elisa Baranski
Lima, Carlos Henrique de Azeredo
Miranda, Renan Lyra
Guterres, Alexandro
Andreiuolo, Felipe
Wildemberg, Luiz Eduardo Armondi
Gadelha, Monica Roberto
author_sort Lamback, Elisa Baranski
collection PubMed
description Background: Somatic mutations in the ubiquitin-specific peptidase 8 (USP8) gene have been described in Cushing’s disease (CD). These mutations increase proopiomelanocortin transcription resulting in ACTH production and seem to correlate with somatostatin receptor type 5 (SST5) expression. Aims: Screen USP8 in patients with corticotropinomas and correlate USP8 mutational status with SST5 expression in CD. Methods: Tumor DNA was extracted and then exon 14 amplified by PCR. SST5 was assessed by immunohistochemistry (clone UMB4) and quantified multiplying the percentage of positive cells (0,0%; <10%,1;10-50%, 2; 51-80%, 3; >80%, 4) and intensity (mild, 1; moderate, 2; intense, 3), giving a score (IRS) from 0-12 with ≥ 6 considered high. Results: Among 59 patients, 38 had CD and 21 silent corticotropinomas. In CD, 13 (34.2%) patients had pathogenic mutations (6 had p.Ser719del; 5 had p.Pro720Arg and 2 had p.Pro720Gln). In the mutated CD group, all were women and had median age of 34.5 years (20-46). Median ACTH was 64.7pg/mL [(34.8-330.0), normal <46], urinary free cortisol (UFC) 435.0μg/24h [(87.0-1386.0), normal <100], cortisol after overnight 1mg dexamethasone suppression test (ODST) 17.4μg/dL [(5.0-48.7), normal <1.8], salivary cortisol (SC) 8.1μg/dL [(1.0-15.5), normal <0.35]. Median largest tumor size was 0.9 cm (0-1.9), ki-67 1.7 (0.2-10.0) and IRS 12 (1-12). In wild-type CD group, 19 (76.0%) were women and had median age was 35.0 years old (14-62). Median ACTH was 59.7 (39.0-137.0), UFC 305.8 (77.0-1302.0), cortisol after ODST 23.6 (10.0-33.3), SC 0.67 (0.27-1.28). Median largest tumor diameter 0.7cm (0-3.3), ki-67 1.8 (0.2-10) and IRS 4 (0-12). SC was higher in mutated group compared to wild-type (p=0.001) as well as IRS (p=0.009). In silent corticotropinomas, 2 (9.5%) had pathogenic mutations (1 p.Ser718Pro and 1 p.Pro720Arg): male, 36 years old, 3.2 cm tumor, Ki-67 4%, IRS 6; and female, 52 years old, 3.4 cm tumor, Ki-67 2.5%, IRS 12, respectively. One tumor had a variant not reported as pathogenic (p.Thr739Ala): male, 46 years old, 3.7 cm tumor, Ki-67 0.5%, IRS 0. USP8-wild-type silent corticotropinomas had IRS 0-2. Conclusion: One third of CD patients presented with somatic USP8 mutation. Similar to another study, about 10% of silent corticotropinomas also presented somatic USP8 mutation. Expression of SST5 was high in USP8-mutated CD and higher than wild-type group.
format Online
Article
Text
id pubmed-8090680
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80906802021-05-12 USP8 Somatic Mutations in Cushing’s Disease and Silent Corticotropinomas Lamback, Elisa Baranski Lima, Carlos Henrique de Azeredo Miranda, Renan Lyra Guterres, Alexandro Andreiuolo, Felipe Wildemberg, Luiz Eduardo Armondi Gadelha, Monica Roberto J Endocr Soc Neuroendocrinology and Pituitary Background: Somatic mutations in the ubiquitin-specific peptidase 8 (USP8) gene have been described in Cushing’s disease (CD). These mutations increase proopiomelanocortin transcription resulting in ACTH production and seem to correlate with somatostatin receptor type 5 (SST5) expression. Aims: Screen USP8 in patients with corticotropinomas and correlate USP8 mutational status with SST5 expression in CD. Methods: Tumor DNA was extracted and then exon 14 amplified by PCR. SST5 was assessed by immunohistochemistry (clone UMB4) and quantified multiplying the percentage of positive cells (0,0%; <10%,1;10-50%, 2; 51-80%, 3; >80%, 4) and intensity (mild, 1; moderate, 2; intense, 3), giving a score (IRS) from 0-12 with ≥ 6 considered high. Results: Among 59 patients, 38 had CD and 21 silent corticotropinomas. In CD, 13 (34.2%) patients had pathogenic mutations (6 had p.Ser719del; 5 had p.Pro720Arg and 2 had p.Pro720Gln). In the mutated CD group, all were women and had median age of 34.5 years (20-46). Median ACTH was 64.7pg/mL [(34.8-330.0), normal <46], urinary free cortisol (UFC) 435.0μg/24h [(87.0-1386.0), normal <100], cortisol after overnight 1mg dexamethasone suppression test (ODST) 17.4μg/dL [(5.0-48.7), normal <1.8], salivary cortisol (SC) 8.1μg/dL [(1.0-15.5), normal <0.35]. Median largest tumor size was 0.9 cm (0-1.9), ki-67 1.7 (0.2-10.0) and IRS 12 (1-12). In wild-type CD group, 19 (76.0%) were women and had median age was 35.0 years old (14-62). Median ACTH was 59.7 (39.0-137.0), UFC 305.8 (77.0-1302.0), cortisol after ODST 23.6 (10.0-33.3), SC 0.67 (0.27-1.28). Median largest tumor diameter 0.7cm (0-3.3), ki-67 1.8 (0.2-10) and IRS 4 (0-12). SC was higher in mutated group compared to wild-type (p=0.001) as well as IRS (p=0.009). In silent corticotropinomas, 2 (9.5%) had pathogenic mutations (1 p.Ser718Pro and 1 p.Pro720Arg): male, 36 years old, 3.2 cm tumor, Ki-67 4%, IRS 6; and female, 52 years old, 3.4 cm tumor, Ki-67 2.5%, IRS 12, respectively. One tumor had a variant not reported as pathogenic (p.Thr739Ala): male, 46 years old, 3.7 cm tumor, Ki-67 0.5%, IRS 0. USP8-wild-type silent corticotropinomas had IRS 0-2. Conclusion: One third of CD patients presented with somatic USP8 mutation. Similar to another study, about 10% of silent corticotropinomas also presented somatic USP8 mutation. Expression of SST5 was high in USP8-mutated CD and higher than wild-type group. Oxford University Press 2021-05-03 /pmc/articles/PMC8090680/ http://dx.doi.org/10.1210/jendso/bvab048.1328 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology and Pituitary
Lamback, Elisa Baranski
Lima, Carlos Henrique de Azeredo
Miranda, Renan Lyra
Guterres, Alexandro
Andreiuolo, Felipe
Wildemberg, Luiz Eduardo Armondi
Gadelha, Monica Roberto
USP8 Somatic Mutations in Cushing’s Disease and Silent Corticotropinomas
title USP8 Somatic Mutations in Cushing’s Disease and Silent Corticotropinomas
title_full USP8 Somatic Mutations in Cushing’s Disease and Silent Corticotropinomas
title_fullStr USP8 Somatic Mutations in Cushing’s Disease and Silent Corticotropinomas
title_full_unstemmed USP8 Somatic Mutations in Cushing’s Disease and Silent Corticotropinomas
title_short USP8 Somatic Mutations in Cushing’s Disease and Silent Corticotropinomas
title_sort usp8 somatic mutations in cushing’s disease and silent corticotropinomas
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090680/
http://dx.doi.org/10.1210/jendso/bvab048.1328
work_keys_str_mv AT lambackelisabaranski usp8somaticmutationsincushingsdiseaseandsilentcorticotropinomas
AT limacarloshenriquedeazeredo usp8somaticmutationsincushingsdiseaseandsilentcorticotropinomas
AT mirandarenanlyra usp8somaticmutationsincushingsdiseaseandsilentcorticotropinomas
AT guterresalexandro usp8somaticmutationsincushingsdiseaseandsilentcorticotropinomas
AT andreiuolofelipe usp8somaticmutationsincushingsdiseaseandsilentcorticotropinomas
AT wildembergluizeduardoarmondi usp8somaticmutationsincushingsdiseaseandsilentcorticotropinomas
AT gadelhamonicaroberto usp8somaticmutationsincushingsdiseaseandsilentcorticotropinomas